Sleep Apnea: The Hidden Productivity Killer
Unaddressed sleep apnea is costing businesses and economies billions, and it's time to shine a light on this silent issue.
A recent study has revealed a shocking truth: obstructive sleep apnea, a common breathing disorder, is not only widespread but also a significant drain on productivity. With an estimated 22.8% of adults in the USA and 19.5% in the UK affected, the economic impact is staggering.
The study linked untreated sleep apnea to substantial workplace losses, highlighting the issue of absenteeism and presenteeism. In simple terms, this means that employees are either absent from work or present but not performing at their best due to fatigue and sleep-related issues. The numbers are eye-opening: an estimated annual loss of $180.2 billion in the USA and $4.22 billion in the UK, with each affected worker losing an average of $3,727 and £1,840, respectively.
But here's where it gets controversial: the treatment costs for sleep apnea are significantly lower than the productivity losses. Continuous Positive Airway Pressure (CPAP) therapy, a standard treatment, costs around $1,661 per patient in the USA and £1,363 in the UK. Yet, the potential economic gains from better identification, access, and adherence to treatment are substantial.
The authors emphasize that these figures may even be conservative, as they don't account for increased healthcare costs related to cardiovascular issues, diabetes, and dementia, which are often linked to sleep apnea. Additionally, the study relied on self-reported symptoms rather than objective sleep studies, which could underestimate the severity of the condition.
So, is it time for workplaces to consider screening for sleep apnea? A linked editorial argues that with an estimated 80-85% of cases undiagnosed, and those with daytime sleepiness being at higher risk of workplace injuries, screening could be a game-changer.
The editorial suggests that with improved risk algorithms, low-cost home sleep testing, and a variety of treatment options, workplace screening in high-risk occupations could be a viable solution. However, it also acknowledges the potential challenges, such as job security concerns, insurance implications, and privacy issues.
The next step, according to the editorial, should be a trial of workplace screening in a high-risk group, like professional drivers, to determine if identifying and treating sleep apnea can lead to reduced accidents and improved productivity.
This hidden multi-billion-dollar hit to productivity is a call to action for employers and policymakers. By addressing sleep apnea, we can not only improve the lives of affected individuals but also boost economic performance. It's time to wake up to the potential benefits of tackling this silent epidemic.
